Concepedia

Kerry Klussman

KK

Statistics

Publications

26

Citations

4.3K

H-Index

22

Active since

1992

Affiliations

Seagen (United States)(Current)

Bristol-Myers Squibb (United States)

Bristol-Myers Squibb (Germany)

University of Washington

Fred Hutch Cancer Center

Kerry Klussman is an author at Seagen (United States) specializing in immunology, oncology, and life sciences.

ORCID

Publications per year

1992–2023

26

Publications

26

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood · 2003 · 921 citations

, , +11

4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses

Walter W. Shuford, Kerry Klussman, Douglas D. Tritchler et al. · The Journal of Experimental Medicine · 1997 · 792 citations · Full text

, , +17

Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes

Nitin K. Damle, Kerry Klussman, Peter S. Linsley et al. · The Journal of Immunology · 1992 · 392 citations

, , +17

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey et al. · Blood · 2013 · 386 citations

, , +13

The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Alan F. Wahl, Kerry Klussman, Jennifer Thompson et al. · PubMed · 2002 · 212 citations

, , +16

1–5 of 26